Cargando…

A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding

Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding domain (RBD) specific monoclonal Ab (mAb) 82A6 wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Yingyi, Song, Shuyi, Luo, Feiyang, Han, Xiaojian, Hu, Chao, Wang, Yingming, Li, Shenglong, Wang, Wang, Zhang, Huajun, Zhang, Bo, Li, Tingting, Jin, Aishun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289697/ https://www.ncbi.nlm.nih.gov/pubmed/34325131 http://dx.doi.org/10.1016/j.bbrc.2021.07.062

Ejemplares similares

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
por: Mu, Song, et al.
Publicado: (2022)

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
por: Han, Xiaojian, et al.
Publicado: (2021)

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
por: Li, Tingting, et al.
Publicado: (2021)

Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies
por: Li, Shenglong, et al.
Publicado: (2020)

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains
por: Gao, Fengxia, et al.
Publicado: (2021)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients
por: Li, Luo, et al.
Publicado: (2021)

Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape
por: Zhao, Zhennan, et al.
Publicado: (2022)

Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2
por: Chu, Xiaoyu, et al.
Publicado: (2023)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay
por: Zhang, Hui, et al.
Publicado: (2022)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Identification of cross-reactive CD8(+) T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
por: Hu, Chao, et al.
Publicado: (2021)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix
por: Tang, Haoneng, et al.
Publicado: (2022)

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
por: Nai, Yaru, et al.
Publicado: (2021)

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants
por: Xu, Hua, et al.
Publicado: (2021)

Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice
por: Ke, Qian, et al.
Publicado: (2022)

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response
por: Su, Qiu-Dong, et al.
Publicado: (2021)

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
por: Yan, Qihong, et al.
Publicado: (2021)

Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
por: Errico, John M., et al.
Publicado: (2021)

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
por: Dickey, Thayne H., et al.
Publicado: (2022)

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
por: Connelly, Guinevere G., et al.
Publicado: (2022)

Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice
por: Zhang, Quan, et al.
Publicado: (2023)

Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response
por: Long, Qiong, et al.
Publicado: (2022)

MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
por: Castro, Andrea, et al.
Publicado: (2020)

An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity
por: Kostin, N. N., et al.
Publicado: (2022)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
por: Wang, Zheng, et al.
Publicado: (2023)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kug1eohdndm5buh8p82o23n77l